Melanotic Neuroectodermal Tumor of Infancy (MNTI) is a very rare pediatric neoplasm of neural crest origin. In most cases, it develops in infants as a localized tumor of the maxilla, and surgery is usually curative. In less than 10% of patients with inoperable, metastatic or persistently recurring MNTI, chemotherapy (CHT) may be considered; however, its role is still unclear. The aim of our study was to assess the efficacy of CHT in children with large, inoperable, metastatic and/or recurrent MNTI. Four such infants, treated with CHT in Polish and German centers of pediatric oncology, were presented. Additionally, a systematic literature search of the PubMed/MEDLINE, Scopus and Web of Science databases was performed, yielding 38 similar cases within the last 42 years. Neoadjuvant CHT, based mainly on the protocols for neuroblastoma, was often effective, allowing for complete delayed surgery in most cases. However, the role of adjuvant CHT in preventing recurrences after incomplete resection of MNTI remains unclear. Disseminated inoperable MNTI was almost universally associated with poor response to CHT and unfavorable outcome. Further investigations to elaborate standards of management in patients with inoperable, metastatic or persistently recurring MNTIs are necessary to improve outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345623 | PMC |
| http://dx.doi.org/10.3390/cancers13153872 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Anticancer Res
January 2025
Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
Article Synopsis
- A study explored salvage chemotherapy using capecitabine plus oxaliplatin (XELOX) for gastric cancer patients who couldn't tolerate or were resistant to cisplatin, but it was halted due to low patient enrollment.
- 12 patients participated, revealing a disease control rate of 90% and a response rate of 30%, with median progression-free survival of 4.2 months and overall survival of 7.1 months.
- Common severe side effects included fatigue and low potassium levels, but there were no treatment-related deaths, suggesting XELOX might be beneficial for these patients.
Managing Hypoglycaemia in Patients With Insulinoma-A Tertiary Centre Experience and Review of the Literature.
Clin Endocrinol (Oxf)
December 2024
Department of Diabetes and Endocrinology, Cambridge Cancer Centre and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
The management of hypoglycaemia is pivotal in the care of patients with insulinoma. Blood glucose monitoring and regulation needs careful attention pre- and peri-operatively for patients undergoing surgical resection and as part of the long-term management for patients with inoperable or metastatic disease. Hypoglycaemia symptoms are frequently pervasive and disabling, with many patients showing impaired hypoglycaemia awareness that can lead to life-threatening severe hypoglycaemia.
View Article and Find Full Text PDFClinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.
Int Urol Nephrol
December 2024
Medical Oncology Clinic, Ankara Bilkent City Hospital, 06100, Çankaya, Ankara, Turkey.
Purpose: Most bladder cancers are pure urothelial carcinomas, but a small portion, approximately 5-10%, have variant histology or are non-urothelial in nature. This research sought to examine the features of and treatment strategies for different types of urothelial carcinoma with variant histologies and non-urothelial bladder cancer.
Methods: The study cohort comprised individuals with non-urothelial and variant urothelial bladder cancers treated at two medical centres in Ankara, Turkey, between 2005 and 2024.
Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy.
J Pers Med
December 2024
Department of Radiology, University Hospital Tuebingen, 72076 Tübingen, Germany.
: Current guidelines recommend Cisplatin/Gemcitabine/Durvalumab as first-line treatment for inoperable or recurrent cholangiocarcinoma (CCA). Molecular tumor boards (MTB) have the expertise to support organ-specific tumor boards with evidence-based treatment recommendations for subsequent lines of treatment, based on genomic tumor data and scientific evidence. This study evaluates the adoption of an MTB at a comprehensive cancer center in Germany and whether actionable genetic alterations are associated with specific imaging phenotypes.
View Article and Find Full Text PDFClinicopathologic Characteristics of Breast Cancer Patients Who Had a Pathologic Complete Response after Neoadjuvant Treatment.
Ann Ital Chir
December 2024
Department of General Surgery, Izmir Katip Celebi University, Atatürk Education and Research Hospital, 35620 Izmir, Turkey.
Aim: Breast cancer is the most common cancer in women and is a leading cause of cancer-related mortality. The role of neoadjuvant therapy (NAT) in conjunction with surgical intervention is becoming increasingly prominent in the field of oncology. NAT enhance the probability of breast-conserving surgery in cases of locally advanced breast cancer and in patients with metastatic or inoperable disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!